Ocuphire Pharma Results
Diabetic Retinopathy At a Glance
Current Treatment Landscape Demonstrates Need for Less Invasive Therapies
4.HO
111
MAMMA
There are ~8M adults in the
U.S. with DR¹
The number of people with
DR expected to increase more
than 14M by 2050
Ocuphire
PHARMA
DR/DME affects about 1 in 4
people with type 1 and type 2 diabetes
O
56% of patients
reported anxiety related
to anti-VEGF treatment
DR is the leading cause
of blindness among
working-age adults
$13B
(2020)
Global Intravitreal
Injection Revenues in
AMD, DME and
BRVO4
If untreated, DR can rob
people of their vision
prematurely2,3
Majority of moderate to severe patients
with DR are not treated with anti-VEGF
due to injection fear and burden
Source:
1. American Diabetes Association; International Diabetes Federation; Healthline; *Ocuphire internal analysis and assumptions;
2. Das UN. DME, retinopathy and age-related macular degeneration as inflammatory conditions. Arch Med Sci. 2016;12(5):1142-1157. doi:10.5114/aoms.2016.61918
3. Patient survey adapted from Lions International Foundation and International Diabetes Foundation-Europe; Meltzer 2000
4. Guidehouse Triangulation of Global Data, Market Scope and Investor Forecasts (2020) AMD = Age-Related Macular Degeneration; DME = Diabetic Macular Edema; BRVO = Branch Retinal Vein Occlusion
19View entire presentation